Abstract
Aim: Numerous drugs are being widely prescribed for COVID-19 treatment without any direct evidence for the drug safety/efficacy in patients across diverse ethnic populations. Materials & methods: We analyzed whole genomes of 1029 Indian individuals (IndiGen) to understand the extent of drug-gene (pharmacogenetic), drug-drug and drug-drug-gene interactions associated with COVID-19 therapy in the Indian population. Results: We identified 30 clinically significant pharmacogenetic variants and 73 predicted deleterious pharmacogenetic variants. COVID-19-associated pharmacogenes were substantially overlapped with those of metabolic disorder therapeutics. CYP3A4 , ABCB1 and ALB are the most shared pharmacogenes. Fifteen COVID-19 therapeutics were predicted as likely drug-drug interaction candidates when used with four CYP inhibitor drugs. Conclusion: Our findings provide actionable insights for future validation studies and improved clinical decisions for COVID-19 therapy in Indians.
Keywords: COVID-19 therapies; Indian population; drug–drug interactions; drug–drug–gene interactions; pharmacogenomics.
【저자키워드】 Indian population, covid-19 therapies, Drug–drug interactions, drug–drug–gene interactions, pharmacogenomics., 【초록키워드】 COVID-19, Treatment, therapy, variant, drugs, drug, COVID-19 therapeutics, variants, COVID-19 treatment, Patient, CYP3A4, ABCB1, COVID-19 therapy, inhibitor, pharmacogenomics, drug-drug interaction, Evidence, Drug–drug interactions, Interaction, Deleterious, individual, clinical decision, candidate, validation study, material, whole genome, metabolic disorder, whole genomes, populations, predicted, analyzed, clinically, Numerous, ALB, overlapped, pharmacogenetic, with COVID-19, 【제목키워드】 COVID-19, therapy, Genome,